Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease.
about
Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical CorrelatesCurrent approaches to enhance glutamate transporter function and expressionDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?Striatal glutamate release in L-DOPA-induced dyskinetic animalsPSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffickingBrain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.Motor deficits and altered striatal gene expression in aphakia (ak) mice.Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalingThe substantia nigra conveys target-dependent excitatory and inhibitory outputs from the basal ganglia to the thalamus.Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease.Effects of subthalamic nucleus lesions and stimulation upon corticostriatal afferents in the 6-hydroxydopamine-lesioned ratEthanol-induced alterations of amino acids measured by in vivo microdialysis in rats: a meta-analysis.High-frequency stimulation of the subthalamic nucleus modifies the expression of vesicular glutamate transporters in basal ganglia in a rat model of Parkinson's diseaseStriatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat.Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.Neuroglial plasticity at striatal glutamatergic synapses in Parkinson's diseaseThe role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention.Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's ratsNMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and β-arrestin-1 expression in parkinsonian rats.Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's diseaseIn vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.Role of transcription factor yin yang 1 in manganese-induced reduction of astrocytic glutamate transporters: Putative mechanism for manganese-induced neurotoxicityPharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?Neurometabolic profiles of the substantia nigra and striatum of MPTP-intoxicated common marmosets: An in vivo proton MRS study at 9.4 T.Mapping P2X and P2Y receptor proteins in striatum and substantia nigra: An immunohistological study.Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model.Progressive brain metabolic changes under deep brain stimulation of subthalamic nucleus in parkinsonian rats.Functional modulation of G-protein coupled receptors during Parkinson disease-like neurodegeneration.Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.
P2860
Q26852311-DF851340-E327-4795-85A7-19096F143891Q26996723-4E56EA35-C0DD-4C95-9965-41514AD815FFQ27021464-FAFBE185-8D7F-4111-B62F-958AD7F416D0Q27324133-15A5E634-2897-4519-8D37-A0E0814072C2Q28485942-F58451A0-3CA4-4A30-842A-F067FA1C76CAQ28582674-A5FF6BCF-D09A-4A5B-8D32-871C37D50D60Q30833645-5FE1C6A8-3D33-43E7-A368-772BBFC9EDBDQ33255884-CFD294B0-84B0-4E48-8CAE-CBC32D5BAF67Q33303267-753AE2B3-530C-4294-AFD7-0F7E4BAE5B8EQ33428476-153E266D-3779-4597-A0A6-F85084B60C8BQ33707910-83B97E81-A8B6-47B3-ACB2-7C1DDC323065Q33763197-43335245-1B02-48C6-A805-FA47871F8C4AQ34200166-7998CFC4-3CF6-448C-B324-8CF1A119D8CAQ34503542-C4B219F5-77F9-46A7-9220-9F737563FBD6Q34524675-4E1134F3-CAAE-49E9-8546-AF9150A17915Q34673205-F2C5359C-8709-4A83-9956-7A1C564D6723Q35000569-1545683A-9D4E-48EF-A0FA-4FA7D8ED821EQ35087525-8641BCFE-72C8-4324-B12F-DAA500AF6FD2Q35163198-66FAAB70-86E5-49C6-856E-D6707FC67CCAQ35176103-872474BB-EC64-404A-9CD3-A1E200D2BC33Q36137988-D2633146-02A2-48B4-90D4-BA95BC8A1F48Q36557687-95961F5F-E0F9-4A78-B18E-F6FA2CE43D54Q36738475-49488549-5DCA-44CE-B55F-853FD8E212E0Q36851672-8AC0CB48-E8EE-47B7-9D27-DE3FEE1C6359Q37040535-620952DA-1ED0-41AB-9D60-A874A21F036DQ37132571-4AEE29AA-E2AB-440F-A366-B3CBA9453E7BQ37280179-74BCE029-F602-4712-80C3-1F5DF6625096Q37870701-8781E709-058F-46E5-B11F-00B2053D1ABCQ38063779-6E75EDEB-4D6B-4A36-A29C-F1D01272083BQ38240290-2D1178AB-2944-4203-B2BB-91D636E8CDA8Q38262418-EF1E2881-A8D8-4C79-A519-5F9A926F2155Q38579616-4D5144C7-1027-49BD-88F8-6206A2B5AB92Q38951947-ABA474AE-0308-4F1D-B614-86A2994D3207Q39012371-E8AD7D0E-92B1-4902-9DB5-8B9CBACEAA66Q39060890-D84525E3-C072-4E3D-B5D4-705BE6C458C3Q39959387-CAC80755-C8B5-4137-A40C-0B81B8EBD2D6Q39975159-7A511348-19EF-4338-BD61-DA305F0C38F4Q41657488-E194410F-3A90-4F5F-8EB8-221F70840159Q42174379-4074D616-686D-485D-8195-3BC5E31CD2AFQ42747563-8254B040-9A25-4C51-AC7D-41149363616F
P2860
Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Chronic L-DOPA treatment incre ...... model of Parkinson's disease.
@en
Chronic L-DOPA treatment incre ...... model of Parkinson's disease.
@nl
type
label
Chronic L-DOPA treatment incre ...... model of Parkinson's disease.
@en
Chronic L-DOPA treatment incre ...... model of Parkinson's disease.
@nl
prefLabel
Chronic L-DOPA treatment incre ...... model of Parkinson's disease.
@en
Chronic L-DOPA treatment incre ...... model of Parkinson's disease.
@nl
P2093
P2860
P1476
Chronic L-DOPA treatment incre ...... model of Parkinson's disease.
@en
P2093
P2860
P304
P356
10.1111/J.1460-9568.2004.03591.X
P407
P577
2004-09-01T00:00:00Z